Onco-Innovations Advances ONC010 Manufacturing and Partnerships
Onco-Innovations advances ONC010 manufacturing, partners with Nanosoft Polymers, Nucro-Technics, and Avance Clinical to target cancer resistance via DNA repair inhibition.
This news matters because Onco-Innovations is progressing a novel cancer therapy that targets DNA repair in cancer cells, potentially offering a new treatment option for resistant tumors. The successful scale-up of manufacturing and strategic partnerships bring ONC010 closer to clinical trials, which could lead to improved outcomes for patients with solid tumors that have limited treatment options.
